Short Interest in Virax Biolabs Group Limited (NASDAQ:VRAX) Drops By 49.1%

Virax Biolabs Group Limited (NASDAQ:VRAX) was the recipient of a significant decrease in short interest in November. As of November 30th, there was short interest totalling 144,600 shares, a decrease of 49.1% from the November 15th total of 284,000 shares. Currently, 3.6% of the shares of the company are sold short. Based on an average daily trading volume, of 2,000,000 shares, the short-interest ratio is presently 0.1 days.

Virax Biolabs Group Trading Down 2.5 %

Shares of VRAX stock traded down $0.04 during mid-day trading on Friday, hitting $1.57. 69,742 shares of the stock were exchanged, compared to its average volume of 144,398. Virax Biolabs Group has a 52-week low of $0.60 and a 52-week high of $9.00. The firm has a fifty day moving average of $1.92 and a 200 day moving average of $2.02.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.